Form 8-K - Current report:
SEC Accession No. 0001193125-25-059327
Filing Date
2025-03-20
Accepted
2025-03-20 16:48:17
Documents
18
Period of Report
2025-03-19
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d908870d8k.htm   iXBRL 8-K 35002
2 EX-1.1 d908870dex11.htm EX-1.1 173590
3 EX-5.1 d908870dex51.htm EX-5.1 9507
4 EX-99.1 d908870dex991.htm EX-99.1 7822
8 GRAPHIC g908870dsp50.jpg GRAPHIC 15873
9 GRAPHIC g908870g0320102926191.jpg GRAPHIC 2021
  Complete submission text file 0001193125-25-059327.txt   425145

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA akba-20250319.xsd EX-101.SCH 2836
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE akba-20250319_lab.xml EX-101.LAB 17236
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE akba-20250319_pre.xml EX-101.PRE 10803
21 EXTRACTED XBRL INSTANCE DOCUMENT d908870d8k_htm.xml XML 3539
Mailing Address 245 FIRST STREET CAMBRIDGE MA 02142
Business Address 245 FIRST STREET CAMBRIDGE MA 02142 617-871-2098
Akebia Therapeutics, Inc. (Filer) CIK: 0001517022 (see all company filings)

EIN.: 208756903 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36352 | Film No.: 25757152
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)